Crown Castle International Corp
Change company Symbol lookup
Select an option...
CCI Crown Castle International Corp
DOC Physicians Realty Trust
CYDVF Cypress Development Corp
KEYS Keysight Technologies Inc
HBAN Huntington Bancshares Inc
MMP Magellan Midstream Partners LP
VTI Vanguard Total Stock Market Index Fund ETF Shares
SKX Skechers USA Inc
RMGCW RMG Acquisition Equity III Warrant Exp 08 Feb 2026 *W EXP 02/08/2026
IKNA Ikena Oncology Inc

Real Estate : Equity Real Estate Investment Trusts (REITs) | Large Cap Blend
Company profile

Crown Castle International Corp. is a real estate investment trust, which owns, operates and leases cell towers and route miles of fiber supporting small cells and fiber solutions across United States market. The Company's segments include Towers and Fiber, which includes both small cells and fiber solutions. Its business is providing access, including space or capacity, to its shared communications infrastructure via long-term contracts in various forms, including lease, license, sublease and service agreements. The Towers segment provides access, including space or capacity to its towers, which are geographically dispersed throughout the United States. The towers segment also reflects certain network services relating to its towers. The Fiber segment provides access, including space or capacity, to its route miles of fiber primarily supporting small cell networks and fiber solutions geographically dispersed throughout the United States.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

Tests suggest Regeneron antibody treatment for COVID loses effectiveness against omicron variant: WSJ

6:26 am ET November 30, 2021 (MarketWatch)

Early tests suggest that the COVID-19 antibody treatment developed by Regeneron Pharmaceuticals Inc.(REGN)loses effectiveness against the omicron variant of the coronavirus that causes COVID, but the full impact will only be known in the coming weeks after further testing, the company's president and chief scientific officer George Yancopoulos told the Wall Street Journal on Tuesday. Evercore analysts had raised that issue in a note to clients on Friday Omicron is the variant from South Africa that was classified a 'variant of concern' by the World Health Organization on Friday, that has led several countries to impose restrictions on travel from there and neighboring countries. Separate testing of the antibody developed by Eli Lilly & Co. (LLY) suggests it too is less effective against omicron. Researchers say that some antibody therapies are likely to be vulnerable to omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant. Yancopoulos said the company is already working on alternative antibodies that should hold up well against the variant. "What we have to admit is, in the course of the past six days, our urgency has increased," Dr. Yancopoulos said in an interview. "What started out as a backup plan has now been made a lot more urgent." Regeneron shares were down 2.7% premarket, but have gained 35% in the year to date, while the S&P 500 has gained 24%.

-Ciara Linnane


(END) Dow Jones Newswires

November 30, 2021 06:26 ET (11:26 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.